NM_058216.3:c.3G>C
Variant summary
Our verdict is Uncertain significance. The variant received 4 ACMG points: 4P and 0B. PVS1_ModeratePM2
The NM_058216.3(RAD51C):c.3G>C(p.Met1?) variant causes a start lost change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Consequence
NM_058216.3 start_lost
Scores
Clinical Significance
Conservation
Publications
- breast-ovarian cancer, familial, susceptibility to, 3Inheritance: AD Classification: STRONG, LIMITED Submitted by: Genomics England PanelApp, Labcorp Genetics (formerly Invitae), Ambry Genetics
- Fanconi anemia complementation group OInheritance: AR Classification: STRONG, MODERATE, LIMITED Submitted by: G2P, Labcorp Genetics (formerly Invitae), Ambry Genetics, ClinGen
- hereditary breast ovarian cancer syndromeInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- Fanconi anemiaInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
- hereditary breast carcinomaInheritance: AD Classification: NO_KNOWN Submitted by: ClinGen
Genome browser will be placed here
ACMG classification
Our verdict: Uncertain_significance. The variant received 4 ACMG points.
Variant Effect in Transcripts
ACMG analysis was done for transcript: NM_058216.3. You can select a different transcript below to see updated ACMG assignments.
RefSeq Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| RAD51C | NM_058216.3 | MANE Select | c.3G>C | p.Met1? | start_lost | Exon 1 of 9 | NP_478123.1 | ||
| RAD51C | NM_002876.4 | c.3G>C | p.Met1? | start_lost | Exon 1 of 2 | NP_002867.1 | |||
| RAD51C | NR_103872.2 | n.45G>C | non_coding_transcript_exon | Exon 1 of 8 |
Ensembl Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| RAD51C | ENST00000337432.9 | TSL:1 MANE Select | c.3G>C | p.Met1? | start_lost | Exon 1 of 9 | ENSP00000336701.4 | ||
| RAD51C | ENST00000421782.3 | TSL:1 | c.3G>C | p.Met1? | start_lost | Exon 1 of 2 | ENSP00000391450.2 | ||
| RAD51C | ENST00000482007.5 | TSL:1 | n.3G>C | non_coding_transcript_exon | Exon 1 of 8 | ENSP00000433332.1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 32
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Hereditary breast ovarian cancer syndrome Uncertain:1
According to the ACMG SVI adaptation criteria we chose these criteria: PM2 (supporting pathogenic): absent from gnomAD, BS3 (strong benign): alternative start codon at M10 variants in the first methionine are homologous recombination proficient https://www.sciencedirect.com/science/article/pii/S156878642400020X?via%3Dihub
Fanconi anemia complementation group O Uncertain:1
In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. ClinVar contains an entry for this variant (Variation ID: 956146). This variant has not been reported in the literature in individuals affected with RAD51C-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change affects the initiator methionine of the RAD51C mRNA. The next in-frame methionine is located at codon 10.
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at